DE10105039A1 - Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten - Google Patents
Tripeptid-Derivate für die Behandlung neurodegenerativer KrankheitenInfo
- Publication number
- DE10105039A1 DE10105039A1 DE10105039A DE10105039A DE10105039A1 DE 10105039 A1 DE10105039 A1 DE 10105039A1 DE 10105039 A DE10105039 A DE 10105039A DE 10105039 A DE10105039 A DE 10105039A DE 10105039 A1 DE10105039 A1 DE 10105039A1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- alkoxy
- group
- derived
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 13
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 22
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 125000005843 halogen group Chemical group 0.000 claims abstract description 9
- -1 cinnamoyl residue Chemical group 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 241000024188 Andala Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 22
- 108010025020 Nerve Growth Factor Proteins 0.000 description 20
- 208000024827 Alzheimer disease Diseases 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 11
- 210000001320 hippocampus Anatomy 0.000 description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 239000003470 adrenal cortex hormone Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
- 229960004528 vincristine Drugs 0.000 description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001777 nootropic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 4
- 229960001685 tacrine Drugs 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000002932 cholinergic neuron Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000004559 cerebral degeneration Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000038778 CNTF family Human genes 0.000 description 1
- 108091064557 CNTF family Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100024650 Carbonic anhydrase 3 Human genes 0.000 description 1
- 101710167915 Carbonic anhydrase 3 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101710154250 Small basic protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032450 Surgical Shock Diseases 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 230000001796 anti-degenerative effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105039A DE10105039A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
| PCT/EP2002/001181 WO2002062830A1 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of neurodegenerative diseases |
| JP2002563182A JP2004531480A (ja) | 2001-02-05 | 2002-02-05 | 神経変性疾患の処置のためのトリペプチド誘導体 |
| EP02716727A EP1358204A1 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of neurodegenerative diseases |
| US10/635,696 US20050192228A1 (en) | 2001-02-05 | 2003-08-05 | Tripeptide derivatives for the treatment of neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105039A DE10105039A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10105039A1 true DE10105039A1 (de) | 2002-08-08 |
Family
ID=7672832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10105039A Withdrawn DE10105039A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1358204A1 (enExample) |
| JP (1) | JP2004531480A (enExample) |
| DE (1) | DE10105039A1 (enExample) |
| WO (1) | WO2002062830A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007204314A1 (en) * | 2006-01-13 | 2007-07-19 | Oncoreg Ab | Use of TPP II inhibitors in combination with gamma-irradiation for the treatment of cancer |
| JP6344796B2 (ja) * | 2014-09-30 | 2018-06-20 | 森永乳業株式会社 | 高齢者用アルツハイマー型認知症改善剤 |
| JP6589011B2 (ja) * | 2018-05-17 | 2019-10-09 | 森永乳業株式会社 | 脳機能障害改善用経口組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
| DE4007869A1 (de) * | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | Aminosaeurederivate |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| EP0840614A1 (en) * | 1995-06-13 | 1998-05-13 | Sanofi Winthrop, Inc. | Calpain inhibitors for the treatment of neurodegenerative diseases |
-
2001
- 2001-02-05 DE DE10105039A patent/DE10105039A1/de not_active Withdrawn
-
2002
- 2002-02-05 WO PCT/EP2002/001181 patent/WO2002062830A1/en not_active Ceased
- 2002-02-05 JP JP2002563182A patent/JP2004531480A/ja not_active Withdrawn
- 2002-02-05 EP EP02716727A patent/EP1358204A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004531480A (ja) | 2004-10-14 |
| EP1358204A1 (en) | 2003-11-05 |
| WO2002062830A1 (en) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60003837T2 (de) | Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung | |
| DE69424441T2 (de) | (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger | |
| DE68908971T2 (de) | Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen. | |
| DE69331605T2 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| EP0490379A2 (de) | Diaminosäurederivate und pharmazeutische Zusammensetzungen | |
| DE69637104T2 (de) | Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen | |
| DE60215917T2 (de) | Tripepide und tripepdid-derivte zur behandlung von neurodegenerativen erkrankungen | |
| DE3209330C2 (enExample) | ||
| DE10105039A1 (de) | Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten | |
| DE69330315T2 (de) | Neues bowman-birk inhibitorprodukt zur verwendung als antikrebsmittel | |
| EP0021184A1 (de) | Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin | |
| DE2112057A1 (de) | Neue Penicillinester | |
| DE3239710C2 (de) | Peptid mit Nerven-regenerierenden Eigenschaften | |
| DE1768655B2 (enExample) | ||
| DE19738484C2 (de) | Verwendung von N-Propanoyl-Mannosamin als Medikament | |
| DE69838303T2 (de) | Derivate hydroxyprolin | |
| DE2036935B2 (de) | Diisonicotinsaeurehydrazid-methansulfonat des d(+)2,2'-(aethylendiimino)-di-l- butanols, verfahren zur herstellung desselben und diese verbindung enthaltende arzneimittel | |
| DE60307049T2 (de) | Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS | |
| DE3212027C2 (enExample) | ||
| DE69202594T2 (de) | Zusammensetzung gegen Katarakt. | |
| DE3236484A1 (de) | Tripeptide, verfahren zur herstellung derselben und diese enthaltende arzneimittel | |
| DE10105038A1 (de) | Tripeptide und Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems | |
| EP1499636A2 (de) | Neurotrophe und neuroprotektive peptide | |
| EP0028716A2 (de) | Motilitätssteigernde Peptide und deren Verwendung | |
| DE2143437A1 (de) | Arzneimittel zur Bekämpfung von Virusinfektionen und dessen Verwendung als Zusatz zu Futtermitteln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |